HORMONE RECEPTOR POSITIVE BREAST CANCER AND THERAPY RESISTANCE
Professor Elgene Lim
Laboratory Head Connie Johnson Breast Cancer Research Lab,
Garvan Institute of Medical Research, Sydney &
Oncologist, The Kinghorn Cancer Centre, St Vincent’s Hospital, Sydney
RESEARCHER PROFILE (Filmed in Brisbane, Queensland, Australia | October 2024)
Prof Elgene Lim is a medical oncologist at St Vincent’s Hospital and Head of the Connie Johnson Breast Cancer Research Lab at the Garvan Institute. Following his PhD at the Walter & Eliza Hall Institute where he identified the aberrant cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome as the culprit cells giving rise to breast cancer, he furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School. He was awarded the National Breast Cancer Foundation Practitioner Fellowship in 2014 and returned from Boston to Australia. In 2017, he was awarded the inaugural National Breast Cancer Foundation Endowed Chair, and subsequently appointed the Principal Cancer Theme Lead at UNSW.
His research focus is in the area of breast cancer, specifically bringing laboratory findings into clinical studies and evaluation of novel therapies in clinical trials. His team, in partnership with patients, have established a large panel of patient derived breast cancer avatars in mice, which allow for the study of breast cancer biology and the evaluation of novel therapies.
-
Dr Kelly-Anne Masterman
RESEARCH IN NEEDLE-FREE VACCINE DELIVERY SYSTEM
@ VAXXAS, BRISBANE, QUEENSLAND, AUSTRALIA -
Professor Matthew Kiernan
BRAIN AND MIND CENTRE
@ UNIVERSITY OF SYDNEY, NEW SOUTH WALES AUSTRALIA -
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
